Serious Event

Serious Event

Serious Adverse Events (SAEs) are adverse events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability/incapacity, or are congenital anomalies/birth defects. Each serious event is categorized by term, organ system, assessment type, and source vocabulary to provide standardized reporting across clinical trials.

Serious Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Serious Event

Study -> Results Section -> Adverse Events Module -> Serious Event -> Serious Event Stats

Serious Event


Ignite Creation Date: 2025-12-24 @ 3:07 PM
Ignite Modification Date: 2025-12-25 @ 1:28 PM
NCT ID: NCT03249792
Term: Hypotension
Organ System: Vascular disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA 25.1
Notes: None
Study: NCT03249792
Study Brief: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Serious Event Stats (If Any):

Serious Event Stats

Group ID # Events # Affected # At Risk View
EG000 0 0 1 View
EG001 0 0 1 View
EG002 0 0 1 View
EG003 0 0 2 View
EG004 0 0 3 View
EG005 0 0 3 View
EG006 1 1 6 View
EG007 0 0 4 View
EG008 0 0 6 View
EG009 0 0 2 View
EG010 1 1 13 View
EG011 0 0 11 View
EG012 0 0 16 View
EG013 0 0 13 View
EG014 0 0 4 View
EG015 0 0 8 View
EG016 0 0 14 View
EG017 0 0 7 View
EG018 0 0 6 View
EG019 0 0 3 View
EG020 0 0 3 View
EG021 0 0 3 View
EG022 0 0 4 View
EG023 0 0 4 View
EG024 0 0 1 View
EG025 0 0 1 View
EG026 0 0 1 View
EG027 0 0 1 View
EG028 0 0 2 View
EG029 0 0 1 View
EG030 0 0 1 View
EG031 0 0 1 View